Effects of IAP-EOGBSD on Maternal Vaginal Microbiome, Offspring's Gut Microbiome and Metabolites.

The Effects of Intrapartum Antibiotic Prophylaxis to Prevent Group B Streptococcal Early-onset Disease on Maternal Vaginal Microbiome, Intestinal Microbiome and Immunity of Offspring

In view of the current status of prevention and research on GBS disease in mothers and infants at home and abroad, this project intends to explore the characteristics of vaginal microbiota of GBS-colonized pregnant women in southern China, the impact of IAP prevention of GBS-EOD on vaginal flora, and the effect of IAP prevention of GBS-EOD on intestinal flora and immune production in offspring, so as to improve the ability to prevent and treat GBS-related diseases in mothers and infants and promote maternal and infant health.

This project intends to explore the characteristics of vaginal microbiota of GBS-colonized pregnant women in southern China, the impact of IAP prevention of GBS-EOD on vaginal flora, and the effect of IAP prevention of GBS-EOD on intestinal flora and immune production in offspring, so as to improve the ability to prevent and treat GBS-related diseases in mothers and infants and promote maternal and infant health.

Inclusion Criteria:

• Pregnant women are 18 to 40 years;
• 35 to 41 weeks of pregnancy;
• Singleton pregnancy;
• Plan for vaginal delivery and postpartum care in the research hospital;
• Pregnant women who volunteered to participate in the study.

Exclusion Criteria:

• Have infectious diseases, serious infections and clinical diseases;
• Use of antibiotics in the past 2 weeks;
• Long-term use of drugs due to digestion, immunity, blood, chronic diseases;
• Sexual behavior, vaginal douching and topical medication within 24 hours before sampling;
• Any medical or non-medical condition that the investigator considers inappropriate to participate.